Introducing a Hedera Dx board member: Tobias Silberzahn

We are pleased to introduce Tobias Silberzahn, who joined the Hedera Board in 2025. Tobias brings extensive experience in oncology, precision medicine, and global, regional and country-level real-world evidence generation, making him an extremely valuable addition to our team.

With more than 15 years of experience in healthcare, Tobias combines deep scientific expertise with a strong passion for improving patient outcomes worldwide. Throughout his career he has worked with pharmaceutical and medical device companies, startups, investors, large healthcare players and health systems to drive patient-centered innovation. Tobias Silberzahn is a trained biochemist and immunologist.
‍

‍

‍